Iterum Therapeutics plc (ITRMF) Invested Capital (2017 - 2025)

Iterum Therapeutics has reported Invested Capital for 9 years, with the latest figure at -$7.4 million in Q3 2025.

• On a quarterly basis, Invested Capital fell 435.35% year-over-year to -$7.4 million in Q3 2025; TTM through Sep 2025 was -$7.4 million, a 435.35% decrease from a year earlier, with the FY2024 full-year figure at $10.4 million, up 105.58% from the prior year.
• Invested Capital was -$7.4 million for Q3 2025 at Iterum Therapeutics, down from -$3.9 million in the prior quarter.
• The five-year high for Invested Capital was $79.2 million in Q2 2021, with the low at -$7.4 million in Q3 2025.
• Average Invested Capital over 5 years is $29.5 million, with a median of $18.9 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2025: Invested Capital soared 3532.04% in 2021, then tumbled 435.35% in 2025.
• Over 5 years, Invested Capital stood at $64.8 million in 2021, then slumped by 40.96% to $38.3 million in 2022, then slumped by 86.81% to $5.0 million in 2023, then jumped by 105.58% to $10.4 million in 2024, then plunged by 171.09% to -$7.4 million in 2025.
• The last three Invested Capital figures came in at -$7.4 million (Q3 2025), -$3.9 million (Q2 2025), and -$2.6 million (Q1 2025), per Business Quant data.